Blood test for colon cancer by Guardant Health detects 83% of colon cancers, awaits FDA approval.

A blood test for colon cancer developed by Guardant Health demonstrated promising results in a recent study, detecting 83% of colon cancers. The test, already available for purchase in the U.S. at $895, awaits FDA approval. Although it did not identify many precancerous growths found by colonoscopy, the test offers a new, convenient screening option for a leading cause of cancer deaths.